This research investigates how HIV disrupts the developing immune system in early life. Using a baby monkey model of HIV infection, the study identifies immune signals that either promote or limit infection spread. The findings could guide new immune-targeted therapies that improve survival and long-term outcomes for children living with HIV.

This research develops small-molecule treatments for chikungunya virus using a lock-and-key approach targeting viral proteins. A key challenge—molecular orientation (enantiomers)—was addressed with a new synthesis method producing over 95% effective molecules. The optimized compound, BDGR-651, shows promise as a future antiviral treatment for this debilitating disease.